Related Experiment Video

Updated: Sep 30, 2026

In Vitro Evaluation of the Potentiating Effects of Plant-Derived Molecules on Conventional Biocides
09:21

In Vitro Evaluation of the Potentiating Effects of Plant-Derived Molecules on Conventional Biocides

Published on: May 8, 2026

Clinical efficacy of new antibacterial therapies in at-risk populations

J Lorenz1

  • 1Klinikum Lüdenscheid, Department of Pulmonary and Critical Care, Germany.

The Journal of Infection
|August 2, 2002
PubMed

Insights

New ketolide telithromycin offers effective treatment for serious respiratory tract infections (RTIs), including community-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB), even with widespread antibacterial resistance.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Lower respiratory tract infections (RTIs), such as community-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB), cause significant morbidity and mortality.
  • Common respiratory pathogens like Streptococcus pneumoniae exhibit increasing antibacterial resistance, compromising existing therapies.
  • Certain patient groups, including the very young, elderly, and those with co-morbidities, face higher risks from RTIs.

Purpose of the Study:

  • To evaluate the efficacy of the novel ketolide antibacterial, telithromycin, for empirical treatment of community-acquired RTIs.
  • To assess telithromycin's effectiveness against resistant pathogens and in high-risk patient populations.
  • To determine if telithromycin provides an optimal treatment option for RTIs in the context of widespread antibacterial resistance.

Main Methods:

  • Clinical trials comparing telithromycin to existing antibacterials for lower RTIs.
  • Assessment of telithromycin's activity against a range of respiratory pathogens, including atypical and intracellular bacteria.
  • Evaluation of telithromycin's efficacy in specific patient subgroups, such as the elderly and those with severe infections or pneumococcal bacteraemia.

Main Results:

  • Telithromycin 800 mg once-daily demonstrated equivalent efficacy to current antibacterials for lower RTIs.
  • The drug showed excellent activity in treating CAP and AECB patients at high risk for morbidity and mortality.
  • Telithromycin was highly effective against atypical pathogens and bacteria resistant to beta-lactams and macrolides.

Conclusions:

  • Telithromycin represents a promising new option for the empirical treatment of community-acquired RTIs.
  • Its broad spectrum of activity and efficacy against resistant strains address a critical unmet need in RTI management.
  • Telithromycin offers a valuable therapeutic choice, particularly for vulnerable patient populations and complicated infections.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...